BTIG Initiates Buy Rating on NeOnc Technologies Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 25 2026
0mins
Should l Buy NTHI?
Source: NASDAQ.COM
- Fund Ownership Increase: As of April 24, 2026, 23 funds or institutions reported positions in NeOnc Technologies Holdings, with an increase of 3 owners or 15%, indicating growing market confidence in the company.
- Institutional Share Growth: Total shares owned by institutions rose by 18.35% over the last three months to 2.13 million shares, suggesting sustained interest from institutional investors, which could drive stock price appreciation.
- HighPoint Advisor Group's Increase: HighPoint Advisor Group holds 1.145 million shares, reflecting a 16.98% increase, with a 6.81% rise in portfolio allocation, indicating optimism about the company's future prospects.
- Bank of America Reduction: Although Bank of America holds 224K shares, it has decreased its holdings by 0.98% from the previous quarter, with a 7.89% drop in portfolio allocation, reflecting a waning confidence in NTHI.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTHI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTHI
About NTHI
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insider Buying Signals Strong Confidence Across Key Companies
- NeOnc Technologies Update: CEO Amir Heshmatpour has accumulated nearly $1 million in stock purchases over the past year, indicating strong internal confidence in its CNS cancer treatment platform, especially ahead of upcoming clinical trial data.
- Rivian Investment Activity: Volkswagen's recent commitment of approximately $1 billion in share purchases signals long-term confidence in Rivian's EV technology, potentially enhancing its market share despite not being a traditional insider buy.
- Sportradar Executive Buying: Senior executives at Sportradar have acquired over $4.7 million in shares, suggesting confidence in data monetization and global betting market expansion, which may indicate future growth momentum for the company.
- Northwest Bancshares Activity: A cluster of insider purchases totaling around $200,000 has emerged at Northwest Bancshares, reflecting potential confidence in balance sheet stability and loan portfolio quality, despite the smaller scale of these transactions.
See More
BTIG Initiates Buy Rating on NeOnc Technologies Holdings
- Fund Ownership Increase: As of April 24, 2026, 23 funds or institutions reported positions in NeOnc Technologies Holdings, with an increase of 3 owners or 15%, indicating growing market confidence in the company.
- Institutional Share Growth: Total shares owned by institutions rose by 18.35% over the last three months to 2.13 million shares, suggesting sustained interest from institutional investors, which could drive stock price appreciation.
- HighPoint Advisor Group's Increase: HighPoint Advisor Group holds 1.145 million shares, reflecting a 16.98% increase, with a 6.81% rise in portfolio allocation, indicating optimism about the company's future prospects.
- Bank of America Reduction: Although Bank of America holds 224K shares, it has decreased its holdings by 0.98% from the previous quarter, with a 7.89% drop in portfolio allocation, reflecting a waning confidence in NTHI.
See More
Analysis of Recent Insider Buying Activities
- Bank First Insider Purchase: Director Todd A. Sprang bought 450 shares of BFC at $138.96 each on Wednesday, totaling $62,532, indicating confidence in the company's future performance, with a 4% gain at the day's peak.
- Stock Performance: Currently, Bank First's stock is up about 1.8%, reflecting a positive market reaction to insider buying, which may bolster investor confidence in the company.
- NeOnc Purchase Details: President Amir F. Heshmatpour purchased 10,000 shares of NeOnc Technologies Holdings at $4.90 each for a total of $49,000 on Thursday, demonstrating optimism about the company's future prospects.
- Historical Investment Overview: Heshmatpour has made four prior purchases of NeOnc over the past year, totaling $469,008 at an average cost of $5.86 per share, despite the current 2.3% decline in stock price, indicating confidence in the company's long-term value.
See More
NeOnc Technologies Reports Q4 Losses Widen
- Financial Loss Overview: NeOnc Technologies Holdings reported a GAAP EPS of -$3.20 for Q4, with a net loss of $62.1 million, significantly up from $11.9 million or $0.69 per diluted share in Q4 2024, indicating a deterioration in financial health.
- Year-over-Year Comparison: The widening losses compared to the previous year highlight significant challenges in cost control and revenue growth, which may impact future financing capabilities and investor confidence.
- Market Reaction Expectations: Due to ongoing financial losses, the market remains cautious about NeOnc's future performance, leading investors to potentially reassess their strategies, which could negatively affect the stock price.
- Need for Strategic Adjustments: The company must implement effective measures to improve its financial situation, including optimizing operational efficiency and exploring new revenue streams to address current financial pressures and restore market trust.
See More
NeOnc Technologies to Host Investor Conference Call on March 4, 2026
- Clinical Trial Update: NeOnc Technologies will host a conference call on March 4, 2026, to present initial data from the NEO212-01 clinical trial, showcasing safety and toxicity data of its bioconjugated TMZ platform for CNS cancers, which is expected to enhance investor confidence in the company's R&D capabilities.
- Expert Participation: The call will feature independent Scientific Advisory Board members, including Dr. Henry S. Friedman from Duke University and Dr. Alexandra Miller from NYU Langone Health, whose expertise will provide authoritative support for data interpretation, further enhancing the company's reputation in the biopharmaceutical sector.
- FDA Fast-Track Status: NeOnc's NEO100 and NEO212 therapeutics are currently in Phase II clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status, indicating their potential competitiveness in the market and prospects for future commercialization.
- Patent Protection Advantage: The company holds an extensive patent portfolio licensed from the University of Southern California, covering NEO100, NEO212, and other products, with protections extending to 2038, establishing a solid foundation for NeOnc's long-term development in CNS therapeutics.
See More
New Show to Air Tonight on Bloomberg Television
- Global Broadcast Expansion: New to The Street's latest episode will air tonight at 6:30 PM EST on Bloomberg Television, extending its reach to the U.S., MENA, and Latin America, thereby enhancing international investor engagement and broadening its audience base.
- Biotech Advancements: BioVie Inc. is advancing a clinical trial for Parkinson's disease with 60 patients enrolled, expecting topline data in May 2026, which could significantly bolster its market position in the biopharmaceutical sector if successful.
- Obstructive Sleep Apnea Solutions: Vivos Therapeutics Inc.'s FDA-cleared non-surgical oral appliance aims to provide a long-term solution for the estimated one billion people affected by OSA globally, with strategic growth initiatives targeting direct-to-patient markets.
- Virtual Reality Market Growth: Virtuix Holdings Inc.'s Omni One platform has reported a 138% year-over-year growth in the gaming and fitness sectors, with production capacity supporting potential annual revenues of up to $100 million, indicating strong demand in both consumer and defense markets.
See More
Insider Buying Signals Strong Confidence Across Key Companies
- NeOnc Technologies Update: CEO Amir Heshmatpour has accumulated nearly $1 million in stock purchases over the past year, indicating strong internal confidence in its CNS cancer treatment platform, especially ahead of upcoming clinical trial data.
- Rivian Investment Activity: Volkswagen's recent commitment of approximately $1 billion in share purchases signals long-term confidence in Rivian's EV technology, potentially enhancing its market share despite not being a traditional insider buy.
- Sportradar Executive Buying: Senior executives at Sportradar have acquired over $4.7 million in shares, suggesting confidence in data monetization and global betting market expansion, which may indicate future growth momentum for the company.
- Northwest Bancshares Activity: A cluster of insider purchases totaling around $200,000 has emerged at Northwest Bancshares, reflecting potential confidence in balance sheet stability and loan portfolio quality, despite the smaller scale of these transactions.
See More
BTIG Initiates Buy Rating on NeOnc Technologies Holdings
- Fund Ownership Increase: As of April 24, 2026, 23 funds or institutions reported positions in NeOnc Technologies Holdings, with an increase of 3 owners or 15%, indicating growing market confidence in the company.
- Institutional Share Growth: Total shares owned by institutions rose by 18.35% over the last three months to 2.13 million shares, suggesting sustained interest from institutional investors, which could drive stock price appreciation.
- HighPoint Advisor Group's Increase: HighPoint Advisor Group holds 1.145 million shares, reflecting a 16.98% increase, with a 6.81% rise in portfolio allocation, indicating optimism about the company's future prospects.
- Bank of America Reduction: Although Bank of America holds 224K shares, it has decreased its holdings by 0.98% from the previous quarter, with a 7.89% drop in portfolio allocation, reflecting a waning confidence in NTHI.
See More
Analysis of Recent Insider Buying Activities
- Bank First Insider Purchase: Director Todd A. Sprang bought 450 shares of BFC at $138.96 each on Wednesday, totaling $62,532, indicating confidence in the company's future performance, with a 4% gain at the day's peak.
- Stock Performance: Currently, Bank First's stock is up about 1.8%, reflecting a positive market reaction to insider buying, which may bolster investor confidence in the company.
- NeOnc Purchase Details: President Amir F. Heshmatpour purchased 10,000 shares of NeOnc Technologies Holdings at $4.90 each for a total of $49,000 on Thursday, demonstrating optimism about the company's future prospects.
- Historical Investment Overview: Heshmatpour has made four prior purchases of NeOnc over the past year, totaling $469,008 at an average cost of $5.86 per share, despite the current 2.3% decline in stock price, indicating confidence in the company's long-term value.
See More
NeOnc Technologies Reports Q4 Losses Widen
- Financial Loss Overview: NeOnc Technologies Holdings reported a GAAP EPS of -$3.20 for Q4, with a net loss of $62.1 million, significantly up from $11.9 million or $0.69 per diluted share in Q4 2024, indicating a deterioration in financial health.
- Year-over-Year Comparison: The widening losses compared to the previous year highlight significant challenges in cost control and revenue growth, which may impact future financing capabilities and investor confidence.
- Market Reaction Expectations: Due to ongoing financial losses, the market remains cautious about NeOnc's future performance, leading investors to potentially reassess their strategies, which could negatively affect the stock price.
- Need for Strategic Adjustments: The company must implement effective measures to improve its financial situation, including optimizing operational efficiency and exploring new revenue streams to address current financial pressures and restore market trust.
See More
NeOnc Technologies to Host Investor Conference Call on March 4, 2026
- Clinical Trial Update: NeOnc Technologies will host a conference call on March 4, 2026, to present initial data from the NEO212-01 clinical trial, showcasing safety and toxicity data of its bioconjugated TMZ platform for CNS cancers, which is expected to enhance investor confidence in the company's R&D capabilities.
- Expert Participation: The call will feature independent Scientific Advisory Board members, including Dr. Henry S. Friedman from Duke University and Dr. Alexandra Miller from NYU Langone Health, whose expertise will provide authoritative support for data interpretation, further enhancing the company's reputation in the biopharmaceutical sector.
- FDA Fast-Track Status: NeOnc's NEO100 and NEO212 therapeutics are currently in Phase II clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status, indicating their potential competitiveness in the market and prospects for future commercialization.
- Patent Protection Advantage: The company holds an extensive patent portfolio licensed from the University of Southern California, covering NEO100, NEO212, and other products, with protections extending to 2038, establishing a solid foundation for NeOnc's long-term development in CNS therapeutics.
See More
New Show to Air Tonight on Bloomberg Television
- Global Broadcast Expansion: New to The Street's latest episode will air tonight at 6:30 PM EST on Bloomberg Television, extending its reach to the U.S., MENA, and Latin America, thereby enhancing international investor engagement and broadening its audience base.
- Biotech Advancements: BioVie Inc. is advancing a clinical trial for Parkinson's disease with 60 patients enrolled, expecting topline data in May 2026, which could significantly bolster its market position in the biopharmaceutical sector if successful.
- Obstructive Sleep Apnea Solutions: Vivos Therapeutics Inc.'s FDA-cleared non-surgical oral appliance aims to provide a long-term solution for the estimated one billion people affected by OSA globally, with strategic growth initiatives targeting direct-to-patient markets.
- Virtual Reality Market Growth: Virtuix Holdings Inc.'s Omni One platform has reported a 138% year-over-year growth in the gaming and fitness sectors, with production capacity supporting potential annual revenues of up to $100 million, indicating strong demand in both consumer and defense markets.
See More
